AptaBio Therapeutics Inc
KOSDAQ:293780
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6 710
10 440
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| KR |
A
|
AptaBio Therapeutics Inc
KOSDAQ:293780
|
205.6B KRW |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
382B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
160.4B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.1B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
86.3B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.6B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
48.2B USD |
Loading...
|
Market Distribution
| Min | -163 055.6% |
| 30th Percentile | -2.2% |
| Median | 2.7% |
| 70th Percentile | 6.8% |
| Max | 22 874.8% |
Other Profitability Ratios
AptaBio Therapeutics Inc
Glance View
Aptabio Therapeutics, Inc. operates as a pharmaceutical biotechnology company that develops intractable innovative drugs based on original platform technology. The company is headquartered in Yongin, Gyeonggi-Do and currently employs 28 full-time employees. The company went IPO on 2019-06-12. The firm is developing anti-cancer drugs, drugs for inflammatory and fibrotic diseases and diabetic complications drugs, among others.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for AptaBio Therapeutics Inc is -485.6%, which is above its 3-year median of -7 890.1%.
Over the last 3 years, AptaBio Therapeutics Inc’s Operating Margin has increased from -21 592.8% to -485.6%. During this period, it reached a low of -23 668.7% on Sep 30, 2023 and a high of -485.6% on Oct 30, 2025.